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72, 96, 144, and 240 h postdose for the two oldest groups 
and up to 144 h in the youngest group.
Results Twenty-one patients were enrolled and received 
lipegfilgrastim, seven in each age group. Lipegfilgrastim 
exposure levels were comparable across age groups, with 
concentrations maintained over a prolonged period after 
a single injection. Differences in PD were mainly associ-
ated with chemotherapy type. Most investigator-reported 
adverse events were attributed to chemotherapy and not to 
lipegfilgrastim. Severe adverse events were noted in 57% 
of patients; febrile neutropenia, leukopenia, neutropenia, 
and thrombocytopenia were more frequent among the old-
est patients.
Conclusions Results support the use of a body weight-
adjusted dose to achieve equivalent initial peak exposure 
levels of lipegfilgrastim in children of various ages.
Keywords Chemotherapy · Pediatric · G-CSF · 
Neutropenia · Phase 1 · Pharmacodynamics
Introduction
Dose-intensive chemotherapy provides substantial clinical 
benefit for pediatric patients with nonmetastatic sarcomas, 
as shown by studies indicating that the intensity of chem-
otherapy is correlated with improved outcomes [1]. How-
ever, chemotherapy-induced neutropenia and associated 
infection-related complications may limit optimal dosing 
[2, 3]. Thus, decreasing the severity or shortening the dura-
tion of neutropenia following chemotherapy may facilitate 
administration of intensive chemotherapy and improve effi-
cacy and safety.
The definitions of neutropenia and the associated risk 
factors among children are consistent with those in the 
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chemotherapy, limiting optimal dosing and treatment. 
Lipegfilgrastim is a long-acting granulocyte colony-stim-
ulating factor developed for the management of chemo-
therapy-induced neutropenia. The objectives of this phase 
1, multinational, open-label, single-arm study were to 
characterize the pharmacokinetics (PK) and pharmaco-
dynamics (PD) of a single body weight-adjusted dose 
of lipegfilgrastim and to evaluate the efficacy, safety, and 
tolerability of the drug in children with Ewing family of 
tumors or rhabdomyosarcoma treated with myelosuppres-
sive chemotherapy.
Methods Enrolled patients received lipegfilgrastim 
(100 µg/kg) 24 h after the last chemotherapy treatment in 
week 1. Patients were stratified into three age groups: 2 to 
<6, 6 to <12, and 12 to <18 years. Blood samples for PK 
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Electronic supplementary material The online version of this 
article (doi:10.1007/s00280-016-3216-2) contains supplementary 
material, which is available to authorized users.
 * Margarita B. Belogurova 
 deton.hospital31@inbox.ru
1 Pediatric Oncology and Hematology, City Clinical Hospital 
#31, 3 Dinamo Pr., St. Petersburg, Russian Federation 
197110
2 Department of Surgery, West Ukrainian Specialized 
Children’s Medical Center, Lviv, Ukraine
3 Unit of Solid Tumors, 2nd Department of Pediatrics, 
Semmelweis University, Budapest, Hungary
4 Nuventra, Inc, Durham, NC, USA
5 Teva ratiopharm, Merckle GmbH, Ulm, Germany
156 Cancer Chemother Pharmacol (2017) 79:155–164
1 3
adult population [4]. Granulocyte colony-stimulating factor 
(G-CSF) is routinely administered to adults and children to 
counter dose-limiting effects of chemotherapy. Filgrastim 
is currently approved for use in children as a daily injection 
for up to 14 days [5]. However, the drug’s short half-life 
(~3.5 h) is due primarily to rapid clearance by renal excre-
tion, necessitating a daily injection that may be problematic 
for children. Pegfilgrastim (Neulasta, Amgen Inc., USA), a 
human recombinant G-CSF conjugated at the N terminus 
to a single 20-kDa polyethylene glycol (PEG) molecule, is 
administered to adults as a single injection after each cycle 
of cytotoxic chemotherapy but has not been approved for 
children [6]. Prospective, randomized studies have shown 
that the efficacy and safety of pegfilgrastim are similar to 
those of filgrastim among pediatric patients with sarcoma, 
without evidence for differences in the pharmacologic 
properties between adults and children [7–10].
Lipegfilgrastim (Lonquex, Merckle Biotec GmbH, Ger-
many, Teva Pharmaceuticals, Israel) is comparable to peg-
filgrastim. It is a long-acting form of filgrastim comprised 
of a single PEG molecule conjugated to filgrastim at the 
natural G-CSF glycosylation site via a carbohydrate linker. 
It has been proposed that lipegfilgrastim and pegfilgrastim 
share the same elimination pathway by neutrophil-mediated 
clearance, which is saturated at higher doses [11]. How-
ever, results from a recent preclinical study suggested that 
lipegfilgrastim is more resistant to degradation and retains 
greater functional activity than pegfilgrastim following 
exposure to purified human neutrophil elastase or isolated 
human neutrophils [12]. Consistent with a self-regulating 
clearance mechanism, serum lipegfilgrastim concentrations 
decline slowly during the initial neutropenic phase follow-
ing chemotherapy and decline rapidly as the neutrophil 
pool recovers [13].
Lipegfilgrastim is approved by the European Medicines 
Agency for reducing the duration of neutropenia and the 
incidence of febrile neutropenia in adult patients treated 
with cytotoxic chemotherapy; this approval was based on 
a randomized phase 3, active-controlled study with breast 
cancer patients [14] and a randomized phase 3, placebo-
controlled study with lung cancer patients [15]. In two 
studies conducted in adult patients with breast cancer, 
mean peak concentrations (Cmax) of 227 and 266 ng/mL 
were achieved with median time-to-peak concentration 
(tmax) values of 44 and 48 h, respectively, following a single 
6-mg subcutaneous dose of lipegfilgrastim during cycle 1 
of chemotherapy with doxorubicin and docetaxel. In a sep-
arate study in adult patients with non-small cell lung can-
cer, a similar lipegfilgrastim treatment during chemother-
apy with cisplatin and etoposide resulted in a mean Cmax of 
317 ng/mL and median tmax of 24 h [13].
There is no evidence from clinical studies of any dif-
ferences in pharmacologic properties and mechanism of 
action of pegfilgrastim between adult and pediatric popu-
lations [7–10]. Because dosing is adjusted according to 
body weight, lipegfilgrastim, with a molecular composi-
tion resembling that of pegfilgrastim, is expected to achieve 
peak exposure levels and to display a pharmacologic profile 
in children similar to that previously observed in adults.
The objectives of this study were to characterize the 
pharmacokinetics (PK) and pharmacodynamics (PD) of a 
single body weight-adjusted dose (100 µg/kg) of lipegfil-
grastim administered as a subcutaneous injection and to 
evaluate the efficacy, safety, and tolerability of the drug in 
children with Ewing family of tumors or rhabdomyosar-
coma treated with myelosuppressive chemotherapy.
Materials and methods
Study design
This phase 1, multinational open-label, nonrandomized 
study included a screening period and a 3-week treat-
ment and assessment period. Patients were stratified into 
three age groups: 2 to <6 years, 6 to <12 years, and 12 
to <18 years. Enrollment of patients 2 to <6 years of age 
did not begin until PD and safety data from the two older 
groups were available and reviewed by an independent 
data monitoring committee. The planned sample size of 
21 patients was considered sufficient to allow exploratory 
analysis.
The study was conducted in accordance with the Inter-
national Conference on Harmonisation, Good Clinical 
Practice Consolidated Guideline (E6), any applicable 
national and local laws and regulations, and the Declara-
tion of Helsinki. Written informed consent from parents or 
legal guardians of each patient and assent from adolescent 
patients were obtained prior to study entry. This trial was 
registered at www.clinicaltrials.gov (NCT01585649).
Patients
Eligible patients were children 2 to <18 years of age with 
Ewing family of tumors or rhabdomyosarcoma scheduled 
to receive myelosuppressive chemotherapy. Regimens 
comprised vincristine/ifosfamide/doxorubicin/etoposide 
(VIDE) or vincristine, doxorubicin, and cyclophospha-
mide alternating with ifosfamide and etoposide (VDC/IE) 
for patients with Ewing family of tumors or vincristine/
actinomycin D/cyclophosphamide (VAC), VDC/IE, or ifos-
famide/vincristine/actinomycin D (IVA) for patients with 
rhabdomyosarcoma. Chemotherapy dosages and schedules 
are shown in Table S1.
Inclusion criteria were generally based on those used 
in studies with adults, with the addition of minimum 
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body weight to ensure that sufficient blood volume would 
be drawn, in accordance with recommendations by the 
European Medicines Agency related to clinical trials in 
the pediatric population [16]. Other inclusion criteria 
were body weight ≥15 kg for patients 6 to <18 years of 
age and ≥12.5 kg for patients 2 to <6 years of age, white 
blood cell count >2.5 × 109/L, absolute neutrophil count 
(ANC) ≥1.5 × 109/L, platelet count ≥100 × 109/L (at 
screening and prior to chemotherapy), and Eastern Coop-
erative Oncology Group performance status ≤2 for patients 
≥12 years of age.
Patients were excluded who had prior exposure to fil-
grastim, pegfilgrastim, lenograstim, or any other G-CSF 
in clinical study within 6 months before lipegfilgrastim 
administration; known hypersensitivity to filgrastim, pegfil-
grastim, lenograstim, or any other G-CSF in clinical devel-
opment; history of congenital neutropenia or cyclic neutro-
penia; previous bone marrow or stem cell transplantation or 
radiation to ≥25% of bone marrow for any reason, or any 
therapeutic radiation within 3 weeks before lipegfilgrastim 
administration; ongoing active infection or infectious dis-
ease within 2 weeks before lipegfilgrastim administration; 
or any illness or condition deemed by the study investigator 
to affect the safety of the patient or the evaluation of any 
endpoint.
Treatment
Lipegfilgrastim (10 mg/mL) was administered at 100 µg/
kg by a single subcutaneous injection 24 h (±3 h) after the 
last dose of chemotherapy was completed in week 1 of the 
regimen. The 100-µg/kg dose approximated the 6-mg dose 
used previously in adults on a weight-adjusted basis, and 
the maximum dose in this study was 6 mg. The abdomen 
was the preferred location for injection. Lipegfilgrastim 
was administered on day 4 of VIDE; day 3 of VDC/IE 
or IVA; and day 2, 3, 4, or 6 of VAC (depending on the 
individually chosen VAC regimen). All patients received 
the planned lipegfilgrastim dose. Administration of com-
mercially available G-CSFs was not permitted during the 
study treatment period. Other supportive care was provided 
according to local standards in a manner consistent with the 
protocol.
PK/PD and clinical assessments
In accordance with European Union guidelines, 30–35 mL 
total blood volume was drawn from the youngest group, 
and a maximum of 38 mL was drawn from the two older 
groups for the screening and treatment periods (4 weeks). 
Blood samples for PK analyses were obtained at baseline 
and at 3, 8, 24, 30, 48, 72, 96, 144, and 240 h postdose 
for the two older groups and up to 144 h for the youngest 
group. PK assessments were conducted on an inpatient or 
outpatient basis at the discretion of the investigator. The 
following PK parameters were estimated for each patient 
using noncompartmental analysis of the serum concentra-
tion–time data: Cmax (maximum observed serum concen-
tration), tmax (time to reach observed Cmax), AUC0−t (area 
under the serum concentration–time curve from time 0 
to the last measurable concentration, estimated using the 
linear trapezoidal rule method), AUC0−inf (AUC from 
time 0 to infinity), t1/2 (terminal elimination half-life, esti-
mated by linear regression), MRT (mean residence time), 
CL/F (apparent clearance), and Vz/F (apparent volume of 
distribution).
Blood samples for PD assessments (ANC and CD34+ 
count) were collected before chemotherapy on day 1, 
before lipegfilgrastim administration, and on days 2, 4, 5, 6, 
7, 8, 9, and 10 after lipegfilgrastim administration (except 
for patients in the youngest group weighing between ≥12.5 
and <15 kg). Analysis of PD samples was performed at a 
central laboratory. PD assessments included ANC nadir, 
time to ANC nadir, time to ANC recovery from nadir to 
≥1 × 109/L and to ≥2 × 109/L, and time to ANC recovery 
from first chemotherapy to ≥1 × 109/L and to ≥2 × 109/L. 
For CD34+ cells, area over baseline effect curve, AUC, 
maximum observed CD34+ count, and time to maximum 
observed CD34+ count were estimated.
The primary efficacy variable was the incidence of per 
protocol febrile neutropenia occurring in cycle 1, defined 
by an axillary or external ear temperature >38.3 °C or two 
consecutive readings of >37.8 °C at least 2 h apart, and 
ANC <0.5 × 109/L. ANC and vital signs, including body 
temperature, were measured at baseline and through-
out treatment. Incidence and duration of severe (ANC 
<0.5 × 109/L) and very severe (ANC <0.1 × 109/L) neutro-
penia were secondary measures of efficacy.
Adverse events (AEs) were assessed at screening and 
throughout the 3-week study period. Safety assessment 
comprised reported AEs, clinical laboratory test results, 
vital signs, 12-lead electrocardiography findings, physical 
examination findings, results of spleen sonography, and 
local tolerability at the injection site. The severity of each 
AE was recorded as either mild (easily tolerated), moderate 
(sufficiently discomforting to interfere with daily activity), 
or severe (preventing normal daily activities). A serious AE 
(SAE) was defined as one that resulted in death, was life 
threatening, resulted in persistent or significant incapac-
ity, or necessitated medical intervention to prevent death 
or incapacity. The relationship between an AE and the 
study drug was classified as either “no reasonable possi-
bility” (defined as AEs that were clearly due to extraneous 
causes such as disease or environment, or were considered 
unrelated to study drug after medical review at the time of 
evaluation) or “reasonable possibility” (defined as AEs for 
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which a connection with the study drug could not be ruled 
out with certainty or there was a high degree of certainty 
related to the AE and the study drug).
Statistical analysis
Analyses of PK, PD parameters (ANC and CD34+ 
counts), and investigator-assessed febrile neutropenia were 
conducted in the full analysis set, comprising all enrolled 
patients who received lipegfilgrastim and for whom at 
least one PK parameter could be derived. For all variables, 
only observed data from patients were used; missing data 
were not estimated. PK parameters and CD34+ analyses 
were performed using WinNonlin version 6.1 or later. Data 
points selected for the calculation of the terminal slope for 
each individual profile were used to perform PK analysis 
according to these criteria: The relative R2 of the line on 
semi-logarithmic plots is >0.8, at least three points were 
selected (not including tmax), and the time interval used 
for determining the slope was at least two times the cal-
culated t1/2. Drug concentrations less than the lower limit 
of quantification (LLOQ) were set to 0.5 × LLOQ before 
data analysis. For PD assessments, missing ANC values 
during cycle 1 were estimated using linear interpolation, 
which was performed only within the interval between 
the first and last available ANC measurements for cycle 1. 
Only patients with at least three ANC measurements during 
cycle 1 were considered evaluable.
Assessment of laboratory-defined efficacy (febrile neu-
tropenia and severe/very severe neutropenia) per protocol 
definitions was conducted in the per protocol set, which 
excluded patients with any violation of inclusion/exclusion 
criteria, who had taken prohibited concomitant medica-
tions, who met withdrawal criteria but had not withdrawn, 
who had received incorrect doses of the study drug, or who 
missed assessments that might impact the study results. 
Safety and tolerability were assessed for all patients who 
received the study drug. Descriptive statistics were used for 
continuous and categorical variables and were provided for 
observed data only by stratified age group and by chemo-
therapy. Arithmetic and geometric means, standard devia-
tions, minimum, maximum, median, and coefficients of 
variation were calculated for PK/PD parameters.
Results
Patients
Twenty-three pediatric patients with Ewing family of 
tumors or rhabdomyosarcoma scheduled to receive chem-
otherapy were screened for eligibility; 21 patients at 11 
study centers in five countries (Czech Republic, Hungary, 
Poland, Russia, and Ukraine) met all inclusion criteria and 
were enrolled. All enrolled patients received study treat-
ment and comprised the full analysis set. One patient in 
the youngest group was excluded from efficacy analysis 
because of missing PD data; therefore, 20 patients com-
prised the per protocol set (Figure S1).
Rhabdomyosarcoma was the primary cancer type in the 
youngest group, with embryonal rhabdomyosarcoma as the 
predominant subtype. Ewing sarcoma was most common 
in the two older groups and consisted primarily of Ewing 
tumor of bone (Table 1, Table S2). IVA was the planned 
chemotherapy regimen for most patients in the youngest 
group, and patients in the two older groups were predomi-
nantly treated with VIDE (Table 1).
Pharmacokinetic and pharmacodynamic results
Subcutaneous injection of lipegfilgrastim 100 µg/kg approx-
imately 24 h after the last dose of chemotherapy in week 
1 of the chemotherapy regimen resulted in mean (±SD) 
Cmax values of 292 ± 178 ng/mL in the youngest age group, 
303 ± 144 ng/mL in the mid-age group, and 341 ± 381 ng/
mL in the oldest age group (Table 2). On average, lipegfil-
grastim exposure levels were comparable across age groups, 
with concentrations of drug maintained over a prolonged 
period in each age group after a single injection (Fig. 1). 
Tmax ranged between 45 and 82 h across all age groups 
(Table 2). The PK profile of at least one patient from each 
age group was shifted toward earlier tmax and higher Cmax 
values compared with the remainder of the patients in each 
group, consistent with either more rapid systemic uptake of 
the drug or altered PD that affected the PK of the drug (Fig-
ures S2-S4). The effect was most apparent in one adolescent 
patient, resulting in the oldest age group having the highest 
variance in Cmax (Table 2, Figure S4).
Blood sampling stopped at 144 h for patients in the 
youngest group. Because fewer samples were collected in 
the elimination phase, the predefined conditions for cal-
culating the terminal elimination rate constant and related 
parameters (i.e., t½, AUC0−inf, and CL/F) were not met for 
all patients, resulting in a complete set of PK parameters 
in only three of seven patients and five of seven patients in 
the youngest and oldest age group, respectively, compared 
with all seven patients in the mid-age group. Nevertheless, 
a meaningful PK comparison could be made among the 
groups with respect to lipegfilgrastim exposure parameters 
(Cmax and AUC0−t), tmax, and PK disposition parameters. 
Analysis of variance found no significant difference in the 
systemic exposure of lipegfilgrastim among the age groups 
(Table S3). Moreover, the geometric mean values and 95% 
confidence intervals for lipegfilgrastim MRT were consist-
ent with a significantly prolonged PK disposition in the 
pediatric population (Table 2).
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The mean ANC nadir was higher and the median time 
to ANC nadir from start of chemotherapy was longer in 
the youngest group (Table 3) than in the two older groups. 
The median time to ANC recovery from the start of chemo-
therapy was shorter in the youngest group than in the older 
groups. The median time to ANC recovery from nadir was 
the same in the two younger age groups and longest in the 
oldest group. Notably, patients aged 2 to <6 years received 
predominantly IVA chemotherapy, which is known to be 
associated with a less profound myelosuppressive effect 
than either VAC or VIDE. Patients treated with IVA demon-
strated the highest mean ANC nadir and the shortest median 
ANC recovery time from the start of chemotherapy com-
pared with those receiving either VAC or VIDE (Table 3).
The maximum CD34+ count was lowest and time to 
CD34+ maximum was shortest in the youngest group of 
patients (Table 3). Similar trends were observed for the 
mean area over baseline effect curve and geometric mean 
CD34+ AUC. Differences in median time to maximum 
CD34+ observed between age groups corresponded with 
chemotherapy; IVA was associated with the shortest time 
and VIDE with the longest.
Efficacy
Treatment compliance, calculated as 100× body weight-
adjusted dose/target dose, was approximately 100% for all 
patients. The median body weight-adjusted dose administered 
was 100 µg/kg for all three groups. Eight (38%) of the 21 
patients in the full analysis set experienced febrile neutropenia 
by investigator assessment; in contrast, 4 of 20 patients (20%) 
in the per protocol set had laboratory-defined febrile neutro-
penia. When patients were stratified by age, the incidence of 
febrile neutropenia was highest in the oldest group by investi-
gator- and laboratory-assessed definitions (Figure S5).
Stratification by type of chemotherapy showed that all 
12 patients who received VIDE treatment experienced 
severe neutropenia regardless of age (Figure S6). In con-
trast, none of the four patients who received IVA and two 
of the four patients who received VAC experienced severe 
neutropenia. The duration of severe neutropenia was long-
est in the VIDE group (median 3.5 days) compared with the 
VAC (median 0.5 days) and IVA groups (none).
Safety
Enrolled patients in all age groups each received a single 
dose of lipegfilgrastim; two patients received doses that 
exceeded 6 mg but were in proportion to recorded body 
weight. The mean absolute doses were 1.76, 3.68, and 
4.58 mg for the 2- to <6-year, 6- to <12-year, and 12- to 
<18-year age groups, respectively.
Each of the 21 patients experienced at least one AE, 
with a total of 142 events reported. The most common AEs 
Table 1  Patient demographics and baseline characteristics (full analysis set)
IVA ifosfamide+vincristine+actinomycin D; VAC vincristine+actinomycin D+cyclophosphamide; VIDE vincristine+ifosfamide+doxorubicin
+etoposide
Patients
2 to <6 years
n = 7
6 to <12 years
n = 7




Median age (range), years 3 (2–5) 10 (7–11) 13 (13–16) 10 (2–16)
Sex, n (%)
  Male 5 (71) 3 (43) 4 (57) 12 (57)
  Female 2 (29) 4 (57) 3 (43) 9 (43)
Median weight (range), kg 19.3 (12.8–20) 41.8 (23–44.2) 43.9 (24–63) 32 (12.8–63)
Race, n (%)
  White 7 (100) 7 (100) 7 (100) 21 (100)
Cancer type, n (%)
  Ewing family of tumors 1 (14) 5 (71) 6 (86) 12 (57)
  Rhabdomyosarcoma 6 (86) 2 (29) 1 (14) 9 (43)
Median time from diagnosis (range), mo 0.3 (0.2–1.8) 0.1 (0.1–0.4) 0.2 (0–0.4) 0.3 (0–1.8)
Prior surgery, n (%) 7 (100) 5 (71) 5 (71) 17 (81)
Prior radiation, n (%) 0 0 0 0
Chemotherapy planned, n (%)
  IVA 5 (71) 0 0 5 (24)
  VAC 1 (14) 2 (29) 1 (14) 4 (19)
  VIDE 1 (14) 5 (71) 6 (86) 12 (57)
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Table 2  Summary of 
pharmacokinetic parameters in 
the full analysis set
AUC area under the serum concentration versus time curve; CI confidence interval; CL/F apparent clear-
ance; Cmax maximum serum concentration; CV coefficient of variation; MRT mean residence time fol-
lowing subcutaneous administration; SD standard deviation; T1/2 elimination half-life; Tmax time to reach 
maximum serum concentration; Vz/F apparent volume of distribution during the terminal phase after non-
intravenous administration








tmax, h n = 7 n = 7 n = 7
  Mean (SD) 50.3 (49.5) 45.4 (27.2) 82.2 (42.1)
  Median (min, max) 23.9 (8.0, 144.0) 30.0 (29.9, 96.0) 95.8 (3.0, 142.0)
Cmax, ng/mL
a n = 7 n = 7 n = 7
  Mean (SD) 292 (178) 303 (144) 341 (381)
  Geometric mean (95% CI) 243 (128–460) 256 (128–510) 225 (90–560)
  CV % 61.0 47.5 111.6
t1/2, h n = 3 n = 7 n = 5
  Mean (SD) 29.1 (14.3) 16.7 (3.1) 26.4 (12.6)
  Median (min, max) 27.9 (15.4, 43.9) 17.4 (13.4, 22.4) 19.4 (16.1, 46.5)
AUC0−t, µg*h/mL
a n = 7 n = 7 n = 7
  Geometric mean (95% CI) 17.7 (9.0–35.1) 30.0 (14.8–60.6) 27.4 (13.0–57.9)
  CV % 65.7 47.2 60.7
AUC0–inf, µg*h/mL
a n = 3 n = 7 n = 5
  Geometric mean (95% CI) 26.0 (4.5–149.6) 30.0 (14.8–60.6) 38.4 (20.4–72.0)
  CV % 55.2 47.2 55.9
Vz/F, La n = 3 n = 7 n = 5
  Geometric mean (95% CI) 2.72 (0.44–16.86) 2.86 (1.11–7.32) 4.08 (2.47–6.74)
  CV % 66.4 154.7 49.9
CL/F, mL/ha n = 3 n = 7 n = 5
  Geometric mean (95% CI) 71 (17–300) 120 (53–270) 116 (49–276)
  CV % 62.2 130.0 68.8
MRTsc, ha n = 7 n = 7 n = 7
  Geometric mean (95% CI) 49 (19–131) 79 (67–94) 90 (74–110)
  CV % 42.1 16.7 14.6
Fig. 1  Serum concentration 
versus time plot following a 
single subcutaneous injection 
of lipegfilgrastim by age group 
(full analysis set). Note figure is 
in linear scale
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occurring in more than 15% of patients in any age group 
were neutropenia, febrile neutropenia, thrombocytopenia, 
leukopenia, anemia, abdominal pain, constipation, nausea, 
and stomatitis (Table 4). The highest frequency of hema-
tologic AEs, including febrile neutropenia, thrombocytope-
nia, and leukopenia, was reported in the oldest group.
Treatment-related AEs (all mild in severity) were expe-
rienced by one patient in the 2- to <6-year age group 
(increased neutrophil count) and one in the 6- to <12-year 
age group (back and bone pain).
Severe AEs were experienced by 57% of patients; the 
most common (occurring in >15% of patients in any age 
group) were febrile neutropenia, leukopenia, and neutro-
penia. The incidence of severe hematologic AEs was high-
est in the oldest group (Table S4). None of the severe AEs 
reported were classified as treatment related. No significant 
Table 3  Summary of pharmacodynamic parameters (ANC and CD34+ count) by age and type of chemotherapy
All geometric means were rounded to the nearest whole number
ANC absolute neutrophil count; AUC area under the serum concentration–time curve; IVA ifosfamide+vincristine+actinomycin D; VAC 
vincristine+actinomycin D+cyclophosphamide; VIDE vincristine+ifosfamide+doxorubicin+etoposide
a Mean values and (standard deviation)
b Median (range)
c Geometric mean values and 95% confidence interval
Age group (years) Type of chemotherapy
2 to <6 n = 7 6 to <12 n = 7 12 to <18 n = 7 IVA n = 5 VAC n = 4 VIDE n = 12
ANC nadir, ×109/
La
0.88 (0.76) n = 6 0.21 (0.35) n = 7 0.37 (0.77) n = 7 1.23 (0.71) n = 4 0.85 (0.93) n = 4 0.09 (0.08) n = 12
Time to ANC 
nadir from start 
of chemotherapy, 
daysb
9 (7–17) n = 6 8 (6–12) n = 7 8 (8–10) n = 7 10 (8–17) n = 4 8 (6–12) n = 4 8 (7–10) n = 12
Time to ANC nadir 
from start of 
lipegfilgrastim, 
daysb
6.5 (6–15) n = 6 5 (4–9) n = 7 5 (4–6) n = 7 8 (6–15) n = 4 6 (5–9) n = 4 5 (4–6) n = 12
Time to ANC 
≥2 × 109/L from 
start of chemo-
therapy, daysb
11 (0–13) n = 4 12 (11–13) n = 7 12 (0–15) n = 7 6.5 (0–13) n = 2 11.5 (0–13) n = 4 12 (11–15) n = 12
Time to ANC 
≥2 × 109/L 
from ANC nadir, 
daysb
3 (1–5) n = 4 3 (1–6) n = 7 4 (1–5) n = 7 3 (1–5) n = 2 2.5 (1–6) n = 4 3.5 (2–5) n = 12
ANC AUC, days 
×109/Lc



















9.5 (7–13) n = 6 13 (7–15) n = 7 15 (10–19) n = 7 8 (7–11) n = 4 9.5 (7–13) n = 4 13.5 (11–19) 
n = 12




7 (5–12) n = 6 9 (6–12) n = 7 12 (7–15) n = 7 6 (5–9) n = 4 6.5 (6–12) n = 4 10 (8–15) n = 12
Area over baseline 
effect curve 
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changes in serum chemistries were observed. Similarly, no 
clinically significant changes in spleen size were observed 
via sonography.
No deaths were reported following lipegfilgrastim 
administration. A total of five SAEs, all of which 
necessitated hospitalization, were reported in three 
patients treated with VIDE. One patient (age 10 years) 
had febrile neutropenia and very severe neutropenia, 
which resolved after 2 and 4 days, respectively. A sec-
ond patient (age 13 years) had severe neutropenia and 
febrile neutropenia, which resolved after 4 days, and 
a third (age 14 years) had febrile neutropenia lasting 
3 days. All SAEs were managed with antibiotics and 
ibuprofen. None of the SAEs were considered related to 
lipegfilgrastim.
Discussion
Treatment with dose-intensive chemotherapy for children 
with sarcoma has been limited by myelosuppressive side 
effects and associated infectious complications. Filgrastim 
is the only G-CSF approved in Europe for children as a 
daily injection, which may be uncomfortable for children. 
The long-acting G-CSF pegfilgrastim has been approved 
in Europe for adults but not for children. Few prospective 
studies have evaluated the PK of available G-CSF regimens 
in children with sarcoma [9, 10].
This is the first study to report clinical pharmacology 
data for the long-acting G-CSF lipegfilgrastim in a pedi-
atric population. This study was designed to examine 
the PK, as well as the PD, safety, and efficacy, of a sin-
gle subcutaneous dose of lipegfilgrastim among pediatric 
patients. Overall, the Cmax, AUC0−t, and MRT results of 
this study support the use of a 100-μg/kg dose of lipegfil-
grastim for patients 2 to <18 years of age. Based on lipeg-
filgrastim Cmax, in particular, the use of a body weight-
adjusted dose resulted in early lipegfilgrastim exposure 
levels that were comparable across age groups. Moreo-
ver, the peak exposure levels of lipegfilgrastim in each 
pediatric age group were comparable to those reported in 
various groups of adult cancer patients receiving chemo-
therapy [13]. The observed differences in tmax with lipeg-
filgrastim may be attributed to variability between indi-
vidual patients. Analysis of variance in PK parameters 
of interest detected no differences across age groups, 
although missing data from patients in the youngest and 
oldest groups limit meaningful interpretation of some PK 
parameters.
Some PK values in this study are comparable to those 
observed in pegfilgrastim-supported pediatric patients. 
The average Cmax values of lipegfilgrastim correspond 
with those observed in pegfilgrastim-treated patients [10]. 
The median tmax values observed in this study are compa-
rable with those in pediatric patients after pegfilgrastim 
administration [9, 10]. Similarly, the mean t1/2 values of 
Table 4  Overall adverse events occurring in at least two patients, by age group
Includes treatment-emergent and treatment-related events
n (%) 2 to <6 years
n = 7
6 to <12 years
n = 7





 Neutropenia 4 (57.1) 3 (42.9) 4 (57.1) 11 (52.4)
 Febrile neutropenia 1 (14.3) 2 (28.6) 5 (71.4) 8 (38.1)
 Thrombocytopenia 3 (42.9) 1 (14.3) 4 (57.1) 8 (38.1)
 Leukopenia 2 (28.6) 1 (14.3) 4 (57.1) 7 (33.3)
 Anemia 3 (42.9) 0 3 (42.9) 6 (28.6)
Nonhematologic adverse events
  Abdominal pain 0 3 (42.9) 1 (14.3) 4 (19.0)
  Constipation 1 (14.3) 2 (28.6) 1 (14.3) 4 (19.0)
  Nausea 0 3 (42.9) 1 (14.3) 4 (19.0)
  Stomatitis 2 (28.6) 0 2 (28.6) 4 (19.0)
  Aspartate aminotransferase increase 1 (14.3) 1 (14.3) 1 (14.3) 3 (14.3)
  Decreased appetite 0 2 (28.6) 1 (14.3) 3 (14.3)
  Vomiting 1 (14.3) 0 1 (14.3) 2 (9.5)
  Abdominal pain upper 0 2 (28.6) 0 2 (9.5)
  Alanine aminotransferase increase 0 1 (14.3) 1 (14.3) 2 (9.5)
  Neutrophil count decrease 1 (14.3) 1 (14.3) 0 2 (9.5)
  Back pain 0 2 (28.6) 0 2 (9.5)
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lipegfilgrastim are higher in pediatric patients <6 years of 
age than are those in older children [10]. These trends sug-
gest that lipegfilgrastim and pegfilgrastim, as expected from 
their molecular structures, may share some PK properties.
The mean ANC nadir was highest for the young-
est patients in the study. Differences in ANC counts were 
associated with the types of chemotherapy administered 
(Fig. 2). Patients in the youngest group primarily received 
IVA chemotherapy, which is known to produce less myelo-
suppression than either VAC or VIDE. Among the three 
chemotherapy regimens used in this study, VIDE was the 
most myelosuppressive, with the lowest ANC nadir; how-
ever, lipegfilgrastim has been shown to stimulate the high-
est recovery of neutrophils in patients who received VIDE, 
along with the highest CD34+ level in the recovery period 
(Table 3), compared with the other chemotherapy regimens 
in this study.
The majority of investigator-reported AEs were related 
to chemotherapy and not to lipegfilgrastim. The only seri-
ous AEs were neutropenia and febrile neutropenia, which 
were reported in 3 of 21 patients (14.29%). Stratification by 
type of chemotherapy showed that VIDE treatment, which 
was predominantly received by patients 6 to <18 years of 
age, was associated with the highest incidence of labora-
tory-assessed febrile neutropenia (4/12 patients, or 33%; 
Figure S5), particularly among patients 12 to <18 years of 
age (3/6 patients, or 50%). These results suggest that there 
may be an association between the incidence of febrile 
neutropenia and the age of pediatric patients, with older 
patients experiencing a higher incidence. These combined 
results also raise the possibility of an association between 
febrile neutropenia and either VIDE or the underlying dis-
ease type, particularly among older pediatric patients, as 
VIDE was administered only to patients with Ewing fam-
ily of tumors. Therefore, it is not possible to draw a clear 
conclusion regarding an association between febrile neutro-
penia and patient age, and further study is warranted.
The association between type of chemotherapy and inci-
dence of febrile neutropenia aligns with the few published 
reports on the use of other G-CSFs in pediatric patients. In 
a study of pediatric patients with Ewing sarcoma treated 
with VIDE, Wendelin and colleagues reported febrile neu-
tropenia in 78% and 56% of cycles in which pegfilgrastim 
and filgrastim were given, respectively [17]. Likewise, in a 
retrospective analysis of pediatric patients treated with peg-
filgrastim, André and colleagues reported febrile neutrope-
nia in 47%, 4%, and 33% of patients treated with VIDE, 
VAC, and vincristine/ifosfamide/dactinomycin/doxoru-
bicin, respectively [7].
In a randomized phase 2 study of pediatric patients 
with sarcoma, 68% of those receiving pegfilgrastim and 
83% of patients treated with filgrastim experienced febrile 
neutropenia [10]. Over the course of the present study, 
investigator-assessed febrile neutropenia was recorded in 
38% of patients. Central laboratory findings differ, show-
ing febrile neutropenia in 20% of patients. When patients 
were stratified by age, the incidence of febrile neutropenia 
was highest in the oldest group according to both investi-
gator-assessed (71.4%) and laboratory-assessed (42.9%) 
definitions.
The open-label, uncontrolled design of the present study 
limits the conclusions possible regarding the safety and 
efficacy of lipegfilgrastim in the pediatric population. The 
single injection of lipegfilgrastim prevents further inter-
pretation of individual toxicity experiences or immuno-
genicity. A second, controlled study with a larger cohort of 
pediatric patients with Ewing family of tumors or rhabdo-
myosarcoma treated with IVA, VAC, or VIDE is planned to 
further investigate the efficacy and safety of lipegfilgrastim 
and filgrastim administered over multiple cycles. The 
Fig. 2  Absolute neutrophil 
count by type of chemotherapy 
(full analysis set). Note figure 
is in linear scale. ANC absolute 
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primary efficacy endpoint of this study will be the duration 
of severe neutropenia in cycle 1 by treatment, age group, 
and baseline ANC value. Given the strong effect of chemo-
therapy observed in the present study, the type of chemo-
therapy will be added as a stratification variable.
In conclusion, PK data in this study support the use 
of a 100-μg/kg dose of lipegfilgrastim for patients 2 to 
<18 years of age. Lipegfilgrastim exposure levels were 
comparable across age groups, with concentrations main-
tained over a prolonged period after a single injection. Pre-
liminary evidence suggests that lipegfilgrastim may be safe 
and well tolerated for at least 3 weeks following admin-
istration in the pediatric population studied. Severe AEs 
were associated with chemotherapy, particularly in patients 
receiving VIDE. Febrile neutropenia, either alone or in 
addition to neutropenia, accounted for all reported SAEs, 
which occurred in three patients who received VIDE chem-
otherapy. These PK and safety data support ongoing inves-
tigation of lipegfilgrastim in all three age groups.
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